List of works - Charles E Mowbray

A Concise Synthesis of Trifluoromethyl-Substituted 4-Aryloxy Pyrazoles

A Concise and Selective Synthesis of Novel 5-Aryloxyimidazole NNRTIs

scientific article published on 01 April 2006

Assessment of a pretomanid analogue library for African trypanosomiasis: Hit-to-lead studies on 6-substituted 2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]thiazine 8-oxides

scientific article published on 27 October 2017

Challenges of drug discovery in novel target space. The discovery and evaluation of PF-3893787: a novel histamine H4 receptor antagonist

scientific article

Comparison of the non-nucleoside reverse transcriptase inhibitor lersivirine with its pyrazole and imidazole isomers

scientific article

Discovery of a series of potent and selective human H4 antagonists using ligand efficiency and libraries to explore structure–activity relationship (SAR)

scientific article published on 27 August 2011

Discovery of a small molecule inhibitor through interference with the gp120-CD4 interaction

scientific article

Drug Discovery for Kinetoplastid Diseases: Future Directions

scientific article published on 13 December 2018

Hit and lead criteria in drug discovery for infectious diseases of the developing world

scientific article published on 05 October 2015

In vitro and in vivo pharmacodynamics of three novel antileishmanial lead series.

scientific article published on 31 January 2018

Lersivirine, a Nonnucleoside Reverse Transcriptase Inhibitor with Activity against Drug-Resistant Human Immunodeficiency Virus Type 1

scientific article

Novel Amino-pyrazole Ureas with Potent In Vitro and In Vivo Antileishmanial Activity

scientific article published on 16 November 2015

Novel benzoxaborole, nitroimidazole and aminopyrazoles with activity against experimental cutaneous leishmaniasis

scientific article published on 26 February 2019

Novel indazole non-nucleoside reverse transcriptase inhibitors using molecular hybridization based on crystallographic overlays

scientific article

Optimization of 5-aryloxyimidazole non-nucleoside reverse transcriptase inhibitors

scientific article published on November 2008

Pyrazole NNRTIs 1: design and initial optimisation of a novel template

scientific article published on 13 August 2009

Pyrazole NNRTIs 3: optimisation of physicochemical properties

scientific article published on 14 August 2009

Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate

scientific article published on 27 August 2009

Recent Development of Visceral Leishmaniasis Treatments: Successes, Pitfalls, and Perspectives

article

Small, non-peptide C5a receptor antagonists: Part 1

scientific article published on 31 August 2008

Small, non-peptide C5a receptor antagonists: Part 2

scientific article published on 31 August 2008

Synthesis of novel histamine H4 receptor antagonists

scientific article published on 01 December 2011

Treatment options for second-stage gambiense human African trypanosomiasis

scientific article published on 10 September 2014

List of works by Charles E Mowbray

A Concise Synthesis of Trifluoromethyl-Substituted 4-Aryloxy Pyrazoles

A Concise and Selective Synthesis of Novel 5-Aryloxyimidazole NNRTIs

Assessment of a pretomanid analogue library for African trypanosomiasis: Hit-to-lead studies on 6-substituted 2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]thiazine 8-oxides

Challenges of drug discovery in novel target space. The discovery and evaluation of PF-3893787: a novel histamine H4 receptor antagonist

Comparison of the non-nucleoside reverse transcriptase inhibitor lersivirine with its pyrazole and imidazole isomers

Discovery of a series of potent and selective human H4 antagonists using ligand efficiency and libraries to explore structure–activity relationship (SAR)

Discovery of a small molecule inhibitor through interference with the gp120-CD4 interaction

Drug Discovery for Kinetoplastid Diseases: Future Directions

Hit and lead criteria in drug discovery for infectious diseases of the developing world

In vitro and in vivo pharmacodynamics of three novel antileishmanial lead series.

Lersivirine, a Nonnucleoside Reverse Transcriptase Inhibitor with Activity against Drug-Resistant Human Immunodeficiency Virus Type 1

Novel Amino-pyrazole Ureas with Potent In Vitro and In Vivo Antileishmanial Activity

Novel benzoxaborole, nitroimidazole and aminopyrazoles with activity against experimental cutaneous leishmaniasis

Novel indazole non-nucleoside reverse transcriptase inhibitors using molecular hybridization based on crystallographic overlays

Optimization of 5-aryloxyimidazole non-nucleoside reverse transcriptase inhibitors

Pyrazole NNRTIs 1: design and initial optimisation of a novel template

Pyrazole NNRTIs 3: optimisation of physicochemical properties

Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate

Recent Development of Visceral Leishmaniasis Treatments: Successes, Pitfalls, and Perspectives

Small, non-peptide C5a receptor antagonists: Part 1

Small, non-peptide C5a receptor antagonists: Part 2

Synthesis of novel histamine H4 receptor antagonists

Treatment options for second-stage gambiense human African trypanosomiasis